Physician profile
Sandra L Ehrler
NPI 1235773185
$4,703.41
in general payments reported to CMS, 2019-2025
30 companies · $1,045 in 2025
The $1,045 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $999 · 2022: $760 · 2023: $976 · 2024: $923 · 2025: $1,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,924 · Education: $20.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,923.55 |
| Education | $20.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,226.72 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $498.20 | 2021-2025 | Xifaxan, Relistor, Plenvu |
| Nestle Healthcare Nutrition INC. | $286.89 | 2021-2023 | |
| Gilead Sciences, INC. | $263.58 | 2021-2025 | Epclusa |
| Janssen Biotech, INC. | $245.63 | 2021-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $228.17 | 2021-2025 | Entyvio |
| Ardelyx, INC. | $212.49 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $206.74 | 2021-2024 | Ocaliva |
| Pfizer INC. | $179.16 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $174.31 | 2021-2023 | Rebyota |
| Qol Medical, LLC | $132.76 | 2023-2025 | Sucraid, Sucraid |
| Celgene Corporation | $109.11 | 2021-2024 | Zeposia |
| Braintree Laboratories, INC. | $105.09 | 2021-2025 | Suflave, Sutab |
| Regeneron Healthcare Solutions, INC. | $87.85 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $86.26 | 2023-2025 | Omvoh |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $84.17 | 2021-2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $83.08 | 2024-2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $80.39 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $78.31 | 2025 | Rezdiffra |
| Redhill Biopharma INC. | $58.51 | 2021-2022 | |
| Genzyme Corporation | $52.29 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $35.53 | 2023-2024 | Voquezna |
| Celltrion USA INC. | $34.36 | 2023-2025 | Yuflyma, Vegzelma |
| Ironwood Pharmaceuticals, INC | $33.12 | 2021-2024 | |
| Daiichi Sankyo INC. | $29.56 | 2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.46 | 2023 | Cyltezo |
| Novo Nordisk INC | $21.38 | 2025 | Wegovy |
| Oxford Immunotec USA INC | $18.49 | 2022 | |
| Medtronic, INC. | $13.78 | 2022 | |
| Intra-Sana Laboratories | $13.02 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Ehrler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.